nodes	percent_of_prediction	percent_of_DWPC	metapath
Ondansetron—SLC47A1—Ritonavir—acquired immunodeficiency syndrome	0.104	0.136	CbGbCtD
Ondansetron—CYP3A7—Delavirdine—acquired immunodeficiency syndrome	0.0231	0.0302	CbGbCtD
Ondansetron—CYP3A7-CYP3A51P—Delavirdine—acquired immunodeficiency syndrome	0.0231	0.0302	CbGbCtD
Ondansetron—CYP3A7—Indinavir—acquired immunodeficiency syndrome	0.0199	0.0261	CbGbCtD
Ondansetron—CYP3A7-CYP3A51P—Indinavir—acquired immunodeficiency syndrome	0.0199	0.0261	CbGbCtD
Ondansetron—CYP3A7—Nelfinavir—acquired immunodeficiency syndrome	0.0193	0.0253	CbGbCtD
Ondansetron—CYP3A7-CYP3A51P—Nelfinavir—acquired immunodeficiency syndrome	0.0193	0.0253	CbGbCtD
Ondansetron—CYP3A5—Nevirapine—acquired immunodeficiency syndrome	0.0191	0.025	CbGbCtD
Ondansetron—CYP3A7—Ritonavir—acquired immunodeficiency syndrome	0.0175	0.0229	CbGbCtD
Ondansetron—CYP3A7-CYP3A51P—Saquinavir—acquired immunodeficiency syndrome	0.0175	0.0229	CbGbCtD
Ondansetron—CYP3A7-CYP3A51P—Ritonavir—acquired immunodeficiency syndrome	0.0175	0.0229	CbGbCtD
Ondansetron—CYP3A7—Saquinavir—acquired immunodeficiency syndrome	0.0175	0.0229	CbGbCtD
Ondansetron—CYP3A5—Amprenavir—acquired immunodeficiency syndrome	0.0173	0.0226	CbGbCtD
Ondansetron—CYP3A5—Delavirdine—acquired immunodeficiency syndrome	0.0173	0.0226	CbGbCtD
Ondansetron—CYP2E1—Ritonavir—acquired immunodeficiency syndrome	0.0169	0.0221	CbGbCtD
Ondansetron—CYP1A2—Efavirenz—acquired immunodeficiency syndrome	0.0151	0.0198	CbGbCtD
Ondansetron—CYP3A5—Indinavir—acquired immunodeficiency syndrome	0.0149	0.0196	CbGbCtD
Ondansetron—CYP3A5—Nelfinavir—acquired immunodeficiency syndrome	0.0145	0.019	CbGbCtD
Ondansetron—CYP1A2—Nevirapine—acquired immunodeficiency syndrome	0.0142	0.0186	CbGbCtD
Ondansetron—CYP1A2—Lopinavir—acquired immunodeficiency syndrome	0.0142	0.0186	CbGbCtD
Ondansetron—CYP2C9—Efavirenz—acquired immunodeficiency syndrome	0.0136	0.0179	CbGbCtD
Ondansetron—CYP3A5—Saquinavir—acquired immunodeficiency syndrome	0.0131	0.0172	CbGbCtD
Ondansetron—CYP3A5—Ritonavir—acquired immunodeficiency syndrome	0.0131	0.0172	CbGbCtD
Ondansetron—CYP1A2—Delavirdine—acquired immunodeficiency syndrome	0.0129	0.0169	CbGbCtD
Ondansetron—CYP2C9—Lopinavir—acquired immunodeficiency syndrome	0.0128	0.0168	CbGbCtD
Ondansetron—CYP2C9—Nevirapine—acquired immunodeficiency syndrome	0.0128	0.0168	CbGbCtD
Ondansetron—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.0125	0.0163	CbGbCtD
Ondansetron—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.0117	0.0154	CbGbCtD
Ondansetron—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.0117	0.0154	CbGbCtD
Ondansetron—CYP2C9—Amprenavir—acquired immunodeficiency syndrome	0.0116	0.0152	CbGbCtD
Ondansetron—CYP2C9—Delavirdine—acquired immunodeficiency syndrome	0.0116	0.0152	CbGbCtD
Ondansetron—CYP1A2—Nelfinavir—acquired immunodeficiency syndrome	0.0108	0.0141	CbGbCtD
Ondansetron—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.0106	0.0139	CbGbCtD
Ondansetron—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.0106	0.0139	CbGbCtD
Ondansetron—CYP2C9—Indinavir—acquired immunodeficiency syndrome	0.01	0.0131	CbGbCtD
Ondansetron—CYP1A2—Ritonavir—acquired immunodeficiency syndrome	0.00976	0.0128	CbGbCtD
Ondansetron—CYP2C9—Nelfinavir—acquired immunodeficiency syndrome	0.00972	0.0127	CbGbCtD
Ondansetron—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.00916	0.012	CbGbCtD
Ondansetron—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.00889	0.0116	CbGbCtD
Ondansetron—CYP2C9—Saquinavir—acquired immunodeficiency syndrome	0.00879	0.0115	CbGbCtD
Ondansetron—CYP2C9—Ritonavir—acquired immunodeficiency syndrome	0.00879	0.0115	CbGbCtD
Ondansetron—CYP2C9—Zidovudine—acquired immunodeficiency syndrome	0.00843	0.011	CbGbCtD
Ondansetron—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.00804	0.0105	CbGbCtD
Ondansetron—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.00804	0.0105	CbGbCtD
Ondansetron—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.00793	0.0104	CbGbCtD
Ondansetron—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.00746	0.00977	CbGbCtD
Ondansetron—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.00746	0.00977	CbGbCtD
Ondansetron—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.00675	0.00883	CbGbCtD
Ondansetron—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.00675	0.00883	CbGbCtD
Ondansetron—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.00582	0.00762	CbGbCtD
Ondansetron—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.00565	0.0074	CbGbCtD
Ondansetron—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00511	0.00669	CbGbCtD
Ondansetron—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00511	0.00669	CbGbCtD
Ondansetron—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.0049	0.00642	CbGbCtD
Ondansetron—HTR3A—nerve—acquired immunodeficiency syndrome	0.00248	0.0545	CbGeAlD
Ondansetron—OPRM1—nerve—acquired immunodeficiency syndrome	0.00227	0.05	CbGeAlD
Ondansetron—SLC47A2—digestive system—acquired immunodeficiency syndrome	0.00203	0.0445	CbGeAlD
Ondansetron—SLC47A2—vagina—acquired immunodeficiency syndrome	0.00179	0.0393	CbGeAlD
Ondansetron—HTR4—brain—acquired immunodeficiency syndrome	0.00158	0.0347	CbGeAlD
Ondansetron—SLC47A2—nervous system—acquired immunodeficiency syndrome	0.00157	0.0344	CbGeAlD
Ondansetron—SLC47A2—central nervous system—acquired immunodeficiency syndrome	0.00151	0.0331	CbGeAlD
Ondansetron—HTR1A—blood plasma—acquired immunodeficiency syndrome	0.00127	0.0279	CbGeAlD
Ondansetron—SLC47A2—brain—acquired immunodeficiency syndrome	0.0012	0.0263	CbGeAlD
Ondansetron—CYP1A2—blood plasma—acquired immunodeficiency syndrome	0.000968	0.0213	CbGeAlD
Ondansetron—CYP3A5—blood plasma—acquired immunodeficiency syndrome	0.000934	0.0205	CbGeAlD
Ondansetron—CYP2C9—blood plasma—acquired immunodeficiency syndrome	0.000919	0.0202	CbGeAlD
Ondansetron—CYP2E1—blood plasma—acquired immunodeficiency syndrome	0.000871	0.0191	CbGeAlD
Ondansetron—HTR3A—digestive system—acquired immunodeficiency syndrome	0.000721	0.0159	CbGeAlD
Ondansetron—SLC47A1—digestive system—acquired immunodeficiency syndrome	0.000709	0.0156	CbGeAlD
Ondansetron—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000701	0.0154	CbGeAlD
Ondansetron—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.00069	0.0152	CbGeAlD
Ondansetron—HTR3A—blood—acquired immunodeficiency syndrome	0.000687	0.0151	CbGeAlD
Ondansetron—SLC47A1—blood—acquired immunodeficiency syndrome	0.000675	0.0148	CbGeAlD
Ondansetron—SLC47A1—spinal cord—acquired immunodeficiency syndrome	0.000651	0.0143	CbGeAlD
Ondansetron—OPRM1—blood—acquired immunodeficiency syndrome	0.00063	0.0138	CbGeAlD
Ondansetron—SLC47A1—vagina—acquired immunodeficiency syndrome	0.000626	0.0138	CbGeAlD
Ondansetron—OPRM1—spinal cord—acquired immunodeficiency syndrome	0.000607	0.0133	CbGeAlD
Ondansetron—HTR3A—lung—acquired immunodeficiency syndrome	0.000603	0.0132	CbGeAlD
Ondansetron—SLC47A1—lung—acquired immunodeficiency syndrome	0.000592	0.013	CbGeAlD
Ondansetron—HTR3A—nervous system—acquired immunodeficiency syndrome	0.000558	0.0123	CbGeAlD
Ondansetron—HTR1B—spinal cord—acquired immunodeficiency syndrome	0.000556	0.0122	CbGeAlD
Ondansetron—SLC47A1—nervous system—acquired immunodeficiency syndrome	0.000548	0.012	CbGeAlD
Ondansetron—HTR3A—central nervous system—acquired immunodeficiency syndrome	0.000537	0.0118	CbGeAlD
Ondansetron—SLC47A1—central nervous system—acquired immunodeficiency syndrome	0.000528	0.0116	CbGeAlD
Ondansetron—OPRM1—nervous system—acquired immunodeficiency syndrome	0.000512	0.0112	CbGeAlD
Ondansetron—OPRM1—central nervous system—acquired immunodeficiency syndrome	0.000493	0.0108	CbGeAlD
Ondansetron—HTR1B—nervous system—acquired immunodeficiency syndrome	0.000468	0.0103	CbGeAlD
Ondansetron—HTR1B—central nervous system—acquired immunodeficiency syndrome	0.000451	0.0099	CbGeAlD
Ondansetron—HTR1A—spinal cord—acquired immunodeficiency syndrome	0.000448	0.00985	CbGeAlD
Ondansetron—HTR3A—brain—acquired immunodeficiency syndrome	0.000427	0.00937	CbGeAlD
Ondansetron—SLC47A1—brain—acquired immunodeficiency syndrome	0.000419	0.00921	CbGeAlD
Ondansetron—KCNH2—blood—acquired immunodeficiency syndrome	0.000414	0.0091	CbGeAlD
Ondansetron—SLC47A1—lymph node—acquired immunodeficiency syndrome	0.000405	0.0089	CbGeAlD
Ondansetron—KCNH2—bone marrow—acquired immunodeficiency syndrome	0.000401	0.00881	CbGeAlD
Ondansetron—KCNH2—spinal cord—acquired immunodeficiency syndrome	0.000399	0.00877	CbGeAlD
Ondansetron—OPRM1—brain—acquired immunodeficiency syndrome	0.000391	0.00859	CbGeAlD
Ondansetron—KCNH2—vagina—acquired immunodeficiency syndrome	0.000384	0.00844	CbGeAlD
Ondansetron—HTR1A—nervous system—acquired immunodeficiency syndrome	0.000378	0.0083	CbGeAlD
Ondansetron—CYP1A2—digestive system—acquired immunodeficiency syndrome	0.000372	0.00818	CbGeAlD
Ondansetron—HTR1A—central nervous system—acquired immunodeficiency syndrome	0.000364	0.00799	CbGeAlD
Ondansetron—CYP3A5—digestive system—acquired immunodeficiency syndrome	0.000359	0.00789	CbGeAlD
Ondansetron—HTR1B—brain—acquired immunodeficiency syndrome	0.000358	0.00786	CbGeAlD
Ondansetron—CYP1A2—blood—acquired immunodeficiency syndrome	0.000355	0.00779	CbGeAlD
Ondansetron—CYP2C9—digestive system—acquired immunodeficiency syndrome	0.000353	0.00777	CbGeAlD
Ondansetron—CYP3A5—blood—acquired immunodeficiency syndrome	0.000342	0.00752	CbGeAlD
Ondansetron—CYP2E1—lymphoid tissue—acquired immunodeficiency syndrome	0.000339	0.00745	CbGeAlD
Ondansetron—CYP2C9—blood—acquired immunodeficiency syndrome	0.000337	0.0074	CbGeAlD
Ondansetron—KCNH2—nervous system—acquired immunodeficiency syndrome	0.000336	0.00739	CbGeAlD
Ondansetron—CYP2E1—digestive system—acquired immunodeficiency syndrome	0.000335	0.00736	CbGeAlD
Ondansetron—KCNH2—central nervous system—acquired immunodeficiency syndrome	0.000324	0.00711	CbGeAlD
Ondansetron—CYP2E1—blood—acquired immunodeficiency syndrome	0.000319	0.00701	CbGeAlD
Ondansetron—CYP3A5—vagina—acquired immunodeficiency syndrome	0.000317	0.00697	CbGeAlD
Ondansetron—CYP1A2—lung—acquired immunodeficiency syndrome	0.000311	0.00683	CbGeAlD
Ondansetron—CYP2E1—spinal cord—acquired immunodeficiency syndrome	0.000307	0.00675	CbGeAlD
Ondansetron—CYP3A5—lung—acquired immunodeficiency syndrome	0.0003	0.00659	CbGeAlD
Ondansetron—HTR1A—brain—acquired immunodeficiency syndrome	0.000289	0.00634	CbGeAlD
Ondansetron—CYP2E1—lung—acquired immunodeficiency syndrome	0.00028	0.00615	CbGeAlD
Ondansetron—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000269	0.00592	CbGeAlD
Ondansetron—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.000265	0.00583	CbGeAlD
Ondansetron—CYP2E1—nervous system—acquired immunodeficiency syndrome	0.000259	0.00569	CbGeAlD
Ondansetron—KCNH2—brain—acquired immunodeficiency syndrome	0.000257	0.00565	CbGeAlD
Ondansetron—CYP3A4—blood—acquired immunodeficiency syndrome	0.000257	0.00564	CbGeAlD
Ondansetron—CYP2D6—blood—acquired immunodeficiency syndrome	0.000253	0.00555	CbGeAlD
Ondansetron—CYP2E1—central nervous system—acquired immunodeficiency syndrome	0.000249	0.00548	CbGeAlD
Ondansetron—KCNH2—lymph node—acquired immunodeficiency syndrome	0.000248	0.00546	CbGeAlD
Ondansetron—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000208	0.00458	CbGeAlD
Ondansetron—CYP2D6—nervous system—acquired immunodeficiency syndrome	0.000205	0.00451	CbGeAlD
Ondansetron—Somnolence—Zidovudine—acquired immunodeficiency syndrome	0.000203	0.00114	CcSEcCtD
Ondansetron—Ill-defined disorder—Ritonavir—acquired immunodeficiency syndrome	0.000202	0.00113	CcSEcCtD
Ondansetron—Hypersensitivity—Nevirapine—acquired immunodeficiency syndrome	0.000201	0.00112	CcSEcCtD
Ondansetron—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000201	0.00441	CbGeAlD
Ondansetron—Chest pain—Delavirdine—acquired immunodeficiency syndrome	0.0002	0.00112	CcSEcCtD
Ondansetron—Agitation—Ritonavir—acquired immunodeficiency syndrome	0.0002	0.00112	CcSEcCtD
Ondansetron—Erythema—Lamivudine—acquired immunodeficiency syndrome	0.0002	0.00112	CcSEcCtD
Ondansetron—Anxiety—Delavirdine—acquired immunodeficiency syndrome	0.0002	0.00112	CcSEcCtD
Ondansetron—Discomfort—Delavirdine—acquired immunodeficiency syndrome	0.000198	0.00111	CcSEcCtD
Ondansetron—CYP2E1—brain—acquired immunodeficiency syndrome	0.000198	0.00435	CbGeAlD
Ondansetron—Shock—Efavirenz—acquired immunodeficiency syndrome	0.000198	0.00111	CcSEcCtD
Ondansetron—CYP2D6—central nervous system—acquired immunodeficiency syndrome	0.000197	0.00434	CbGeAlD
Ondansetron—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	0.000197	0.0011	CcSEcCtD
Ondansetron—Fatigue—Zidovudine—acquired immunodeficiency syndrome	0.000197	0.0011	CcSEcCtD
Ondansetron—Flatulence—Lamivudine—acquired immunodeficiency syndrome	0.000197	0.0011	CcSEcCtD
Ondansetron—Nervous system disorder—Efavirenz—acquired immunodeficiency syndrome	0.000197	0.0011	CcSEcCtD
Ondansetron—Malaise—Ritonavir—acquired immunodeficiency syndrome	0.000196	0.0011	CcSEcCtD
Ondansetron—Tremor—Saquinavir—acquired immunodeficiency syndrome	0.000196	0.0011	CcSEcCtD
Ondansetron—Dry mouth—Delavirdine—acquired immunodeficiency syndrome	0.000196	0.0011	CcSEcCtD
Ondansetron—Tachycardia—Efavirenz—acquired immunodeficiency syndrome	0.000196	0.0011	CcSEcCtD
Ondansetron—Pain—Zidovudine—acquired immunodeficiency syndrome	0.000195	0.00109	CcSEcCtD
Ondansetron—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.000195	0.00109	CcSEcCtD
Ondansetron—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.000195	0.00109	CcSEcCtD
Ondansetron—Syncope—Ritonavir—acquired immunodeficiency syndrome	0.000195	0.00109	CcSEcCtD
Ondansetron—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	0.000195	0.00109	CcSEcCtD
Ondansetron—Ill-defined disorder—Saquinavir—acquired immunodeficiency syndrome	0.000194	0.00109	CcSEcCtD
Ondansetron—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	0.000194	0.00109	CcSEcCtD
Ondansetron—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	0.000194	0.00108	CcSEcCtD
Ondansetron—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.000193	0.00108	CcSEcCtD
Ondansetron—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.000193	0.00108	CcSEcCtD
Ondansetron—Agitation—Saquinavir—acquired immunodeficiency syndrome	0.000193	0.00108	CcSEcCtD
Ondansetron—Palpitations—Ritonavir—acquired immunodeficiency syndrome	0.000192	0.00108	CcSEcCtD
Ondansetron—Loss of consciousness—Ritonavir—acquired immunodeficiency syndrome	0.000191	0.00107	CcSEcCtD
Ondansetron—Rash—Didanosine—acquired immunodeficiency syndrome	0.000191	0.00107	CcSEcCtD
Ondansetron—Paraesthesia—Indinavir—acquired immunodeficiency syndrome	0.000191	0.00107	CcSEcCtD
Ondansetron—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.000191	0.00107	CcSEcCtD
Ondansetron—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.000191	0.00107	CcSEcCtD
Ondansetron—Cough—Ritonavir—acquired immunodeficiency syndrome	0.00019	0.00106	CcSEcCtD
Ondansetron—Headache—Didanosine—acquired immunodeficiency syndrome	0.00019	0.00106	CcSEcCtD
Ondansetron—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	0.00019	0.00106	CcSEcCtD
Ondansetron—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.000189	0.00106	CcSEcCtD
Ondansetron—Shock—Delavirdine—acquired immunodeficiency syndrome	0.000189	0.00106	CcSEcCtD
Ondansetron—Malaise—Saquinavir—acquired immunodeficiency syndrome	0.000189	0.00106	CcSEcCtD
Ondansetron—Somnolence—Indinavir—acquired immunodeficiency syndrome	0.000189	0.00106	CcSEcCtD
Ondansetron—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.000189	0.00106	CcSEcCtD
Ondansetron—Convulsion—Ritonavir—acquired immunodeficiency syndrome	0.000189	0.00106	CcSEcCtD
Ondansetron—Feeling abnormal—Zidovudine—acquired immunodeficiency syndrome	0.000188	0.00105	CcSEcCtD
Ondansetron—Syncope—Saquinavir—acquired immunodeficiency syndrome	0.000188	0.00105	CcSEcCtD
Ondansetron—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	0.000188	0.00105	CcSEcCtD
Ondansetron—Tremor—Lamivudine—acquired immunodeficiency syndrome	0.000187	0.00105	CcSEcCtD
Ondansetron—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.000187	0.00105	CcSEcCtD
Ondansetron—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.000187	0.00104	CcSEcCtD
Ondansetron—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000187	0.00104	CcSEcCtD
Ondansetron—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000186	0.00104	CcSEcCtD
Ondansetron—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000186	0.00104	CcSEcCtD
Ondansetron—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000186	0.00104	CcSEcCtD
Ondansetron—Ill-defined disorder—Lamivudine—acquired immunodeficiency syndrome	0.000186	0.00104	CcSEcCtD
Ondansetron—Chest pain—Ritonavir—acquired immunodeficiency syndrome	0.000185	0.00104	CcSEcCtD
Ondansetron—Anxiety—Ritonavir—acquired immunodeficiency syndrome	0.000185	0.00103	CcSEcCtD
Ondansetron—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	0.000184	0.00103	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.000184	0.00103	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000184	0.00103	CcSEcCtD
Ondansetron—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000183	0.00103	CcSEcCtD
Ondansetron—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000183	0.00103	CcSEcCtD
Ondansetron—Discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000183	0.00102	CcSEcCtD
Ondansetron—Cough—Saquinavir—acquired immunodeficiency syndrome	0.000183	0.00102	CcSEcCtD
Ondansetron—Angioedema—Lamivudine—acquired immunodeficiency syndrome	0.000183	0.00102	CcSEcCtD
Ondansetron—Pain—Indinavir—acquired immunodeficiency syndrome	0.000182	0.00102	CcSEcCtD
Ondansetron—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000182	0.00102	CcSEcCtD
Ondansetron—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.000182	0.00102	CcSEcCtD
Ondansetron—Convulsion—Saquinavir—acquired immunodeficiency syndrome	0.000182	0.00102	CcSEcCtD
Ondansetron—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.000181	0.00101	CcSEcCtD
Ondansetron—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000181	0.00101	CcSEcCtD
Ondansetron—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.000181	0.00101	CcSEcCtD
Ondansetron—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.00018	0.00101	CcSEcCtD
Ondansetron—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	0.00018	0.00101	CcSEcCtD
Ondansetron—Malaise—Lamivudine—acquired immunodeficiency syndrome	0.00018	0.00101	CcSEcCtD
Ondansetron—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.00018	0.00101	CcSEcCtD
Ondansetron—Hypotension—Delavirdine—acquired immunodeficiency syndrome	0.00018	0.001	CcSEcCtD
Ondansetron—Syncope—Lamivudine—acquired immunodeficiency syndrome	0.000179	0.001	CcSEcCtD
Ondansetron—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.000179	0.001	CcSEcCtD
Ondansetron—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.000179	0.000999	CcSEcCtD
Ondansetron—Chest pain—Saquinavir—acquired immunodeficiency syndrome	0.000178	0.000998	CcSEcCtD
Ondansetron—Anxiety—Saquinavir—acquired immunodeficiency syndrome	0.000178	0.000995	CcSEcCtD
Ondansetron—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000177	0.000992	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.000177	0.000991	CcSEcCtD
Ondansetron—Discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000176	0.000986	CcSEcCtD
Ondansetron—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	0.000176	0.000983	CcSEcCtD
Ondansetron—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	0.000175	0.00098	CcSEcCtD
Ondansetron—Shock—Ritonavir—acquired immunodeficiency syndrome	0.000175	0.000978	CcSEcCtD
Ondansetron—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.000175	0.000976	CcSEcCtD
Ondansetron—Cough—Lamivudine—acquired immunodeficiency syndrome	0.000174	0.000976	CcSEcCtD
Ondansetron—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000174	0.000976	CcSEcCtD
Ondansetron—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.000174	0.000975	CcSEcCtD
Ondansetron—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000174	0.000973	CcSEcCtD
Ondansetron—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.000174	0.000972	CcSEcCtD
Ondansetron—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.000173	0.00097	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000173	0.00097	CcSEcCtD
Ondansetron—Convulsion—Lamivudine—acquired immunodeficiency syndrome	0.000173	0.000969	CcSEcCtD
Ondansetron—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000173	0.000969	CcSEcCtD
Ondansetron—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.000173	0.000969	CcSEcCtD
Ondansetron—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000173	0.000966	CcSEcCtD
Ondansetron—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	0.000173	0.000965	CcSEcCtD
Ondansetron—Pain—Efavirenz—acquired immunodeficiency syndrome	0.000172	0.000961	CcSEcCtD
Ondansetron—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000172	0.000961	CcSEcCtD
Ondansetron—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000172	0.000961	CcSEcCtD
Ondansetron—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000172	0.00096	CcSEcCtD
Ondansetron—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.000171	0.000958	CcSEcCtD
Ondansetron—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000171	0.000958	CcSEcCtD
Ondansetron—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.000171	0.000956	CcSEcCtD
Ondansetron—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000171	0.000955	CcSEcCtD
Ondansetron—Chest pain—Lamivudine—acquired immunodeficiency syndrome	0.00017	0.000952	CcSEcCtD
Ondansetron—Anxiety—Lamivudine—acquired immunodeficiency syndrome	0.00017	0.000949	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.000169	0.000946	CcSEcCtD
Ondansetron—Urticaria—Indinavir—acquired immunodeficiency syndrome	0.000169	0.000945	CcSEcCtD
Ondansetron—Shock—Saquinavir—acquired immunodeficiency syndrome	0.000168	0.000941	CcSEcCtD
Ondansetron—Discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000168	0.000941	CcSEcCtD
Ondansetron—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.000168	0.00094	CcSEcCtD
Ondansetron—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.000168	0.00094	CcSEcCtD
Ondansetron—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.000168	0.000938	CcSEcCtD
Ondansetron—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000168	0.000938	CcSEcCtD
Ondansetron—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000167	0.000935	CcSEcCtD
Ondansetron—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.000166	0.000931	CcSEcCtD
Ondansetron—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000166	0.00093	CcSEcCtD
Ondansetron—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000166	0.00093	CcSEcCtD
Ondansetron—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.000166	0.000929	CcSEcCtD
Ondansetron—Hypotension—Ritonavir—acquired immunodeficiency syndrome	0.000166	0.000929	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.000166	0.000928	CcSEcCtD
Ondansetron—Rash—Stavudine—acquired immunodeficiency syndrome	0.000166	0.000928	CcSEcCtD
Ondansetron—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.000166	0.000927	CcSEcCtD
Ondansetron—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000166	0.000927	CcSEcCtD
Ondansetron—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	0.000166	0.000926	CcSEcCtD
Ondansetron—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000165	0.000924	CcSEcCtD
Ondansetron—Headache—Stavudine—acquired immunodeficiency syndrome	0.000165	0.000922	CcSEcCtD
Ondansetron—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000165	0.000921	CcSEcCtD
Ondansetron—Pain—Delavirdine—acquired immunodeficiency syndrome	0.000164	0.000919	CcSEcCtD
Ondansetron—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000164	0.000919	CcSEcCtD
Ondansetron—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.000164	0.000919	CcSEcCtD
Ondansetron—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.000164	0.000917	CcSEcCtD
Ondansetron—Rash—Abacavir—acquired immunodeficiency syndrome	0.000163	0.000914	CcSEcCtD
Ondansetron—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000163	0.000913	CcSEcCtD
Ondansetron—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	0.000163	0.000913	CcSEcCtD
Ondansetron—Headache—Abacavir—acquired immunodeficiency syndrome	0.000162	0.000908	CcSEcCtD
Ondansetron—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.000162	0.000905	CcSEcCtD
Ondansetron—Shock—Lamivudine—acquired immunodeficiency syndrome	0.000161	0.000898	CcSEcCtD
Ondansetron—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.00016	0.000895	CcSEcCtD
Ondansetron—Hypotension—Saquinavir—acquired immunodeficiency syndrome	0.00016	0.000894	CcSEcCtD
Ondansetron—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	0.00016	0.000893	CcSEcCtD
Ondansetron—Urticaria—Efavirenz—acquired immunodeficiency syndrome	0.00016	0.000893	CcSEcCtD
Ondansetron—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.000159	0.000888	CcSEcCtD
Ondansetron—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	0.000159	0.000888	CcSEcCtD
Ondansetron—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.000159	0.000887	CcSEcCtD
Ondansetron—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	0.000158	0.000886	CcSEcCtD
Ondansetron—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	0.000158	0.000886	CcSEcCtD
Ondansetron—Somnolence—Ritonavir—acquired immunodeficiency syndrome	0.000158	0.000884	CcSEcCtD
Ondansetron—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	0.000157	0.000879	CcSEcCtD
Ondansetron—CYP2D6—brain—acquired immunodeficiency syndrome	0.000157	0.00344	CbGeAlD
Ondansetron—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.000157	0.000876	CcSEcCtD
Ondansetron—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000156	0.000875	CcSEcCtD
Ondansetron—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	0.000154	0.000859	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000153	0.000858	CcSEcCtD
Ondansetron—Fatigue—Ritonavir—acquired immunodeficiency syndrome	0.000153	0.000857	CcSEcCtD
Ondansetron—Urticaria—Delavirdine—acquired immunodeficiency syndrome	0.000153	0.000854	CcSEcCtD
Ondansetron—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.000153	0.000853	CcSEcCtD
Ondansetron—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	0.000152	0.000853	CcSEcCtD
Ondansetron—Hypotension—Lamivudine—acquired immunodeficiency syndrome	0.000152	0.000853	CcSEcCtD
Ondansetron—Somnolence—Saquinavir—acquired immunodeficiency syndrome	0.000152	0.000851	CcSEcCtD
Ondansetron—Pain—Ritonavir—acquired immunodeficiency syndrome	0.000152	0.00085	CcSEcCtD
Ondansetron—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.000152	0.00085	CcSEcCtD
Ondansetron—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	0.000152	0.00085	CcSEcCtD
Ondansetron—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	0.000152	0.00085	CcSEcCtD
Ondansetron—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000151	0.000846	CcSEcCtD
Ondansetron—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.00015	0.000841	CcSEcCtD
Ondansetron—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.000148	0.000828	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000148	0.000826	CcSEcCtD
Ondansetron—Fatigue—Saquinavir—acquired immunodeficiency syndrome	0.000147	0.000825	CcSEcCtD
Ondansetron—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	0.000147	0.00082	CcSEcCtD
Ondansetron—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	0.000146	0.000819	CcSEcCtD
Ondansetron—Pain—Saquinavir—acquired immunodeficiency syndrome	0.000146	0.000818	CcSEcCtD
Ondansetron—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.000146	0.000818	CcSEcCtD
Ondansetron—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	0.000145	0.000814	CcSEcCtD
Ondansetron—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000145	0.000814	CcSEcCtD
Ondansetron—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000145	0.000813	CcSEcCtD
Ondansetron—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	0.000145	0.000813	CcSEcCtD
Ondansetron—Somnolence—Lamivudine—acquired immunodeficiency syndrome	0.000145	0.000811	CcSEcCtD
Ondansetron—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000144	0.000806	CcSEcCtD
Ondansetron—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.000144	0.000806	CcSEcCtD
Ondansetron—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000144	0.000805	CcSEcCtD
Ondansetron—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000143	0.000801	CcSEcCtD
Ondansetron—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.000142	0.000795	CcSEcCtD
Ondansetron—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.000142	0.000792	CcSEcCtD
Ondansetron—Urticaria—Ritonavir—acquired immunodeficiency syndrome	0.000141	0.00079	CcSEcCtD
Ondansetron—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	0.000141	0.000788	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000141	0.000788	CcSEcCtD
Ondansetron—Fatigue—Lamivudine—acquired immunodeficiency syndrome	0.000141	0.000787	CcSEcCtD
Ondansetron—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.000141	0.000786	CcSEcCtD
Ondansetron—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	0.00014	0.000786	CcSEcCtD
Ondansetron—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	0.00014	0.000786	CcSEcCtD
Ondansetron—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	0.00014	0.000782	CcSEcCtD
Ondansetron—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.00014	0.000781	CcSEcCtD
Ondansetron—Pain—Lamivudine—acquired immunodeficiency syndrome	0.00014	0.000781	CcSEcCtD
Ondansetron—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.000138	0.000771	CcSEcCtD
Ondansetron—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.000137	0.000769	CcSEcCtD
Ondansetron—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000136	0.000761	CcSEcCtD
Ondansetron—Urticaria—Saquinavir—acquired immunodeficiency syndrome	0.000136	0.00076	CcSEcCtD
Ondansetron—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	0.000135	0.000756	CcSEcCtD
Ondansetron—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	0.000135	0.000756	CcSEcCtD
Ondansetron—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000135	0.000756	CcSEcCtD
Ondansetron—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	0.000134	0.000752	CcSEcCtD
Ondansetron—Rash—Indinavir—acquired immunodeficiency syndrome	0.000134	0.00075	CcSEcCtD
Ondansetron—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.000134	0.000749	CcSEcCtD
Ondansetron—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	0.000133	0.000746	CcSEcCtD
Ondansetron—Headache—Indinavir—acquired immunodeficiency syndrome	0.000133	0.000745	CcSEcCtD
Ondansetron—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.000133	0.000743	CcSEcCtD
Ondansetron—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.000131	0.000736	CcSEcCtD
Ondansetron—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.000131	0.000732	CcSEcCtD
Ondansetron—Urticaria—Lamivudine—acquired immunodeficiency syndrome	0.00013	0.000725	CcSEcCtD
Ondansetron—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	0.000129	0.000722	CcSEcCtD
Ondansetron—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	0.000129	0.000722	CcSEcCtD
Ondansetron—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.000128	0.000714	CcSEcCtD
Ondansetron—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.000128	0.000713	CcSEcCtD
Ondansetron—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000127	0.000711	CcSEcCtD
Ondansetron—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000127	0.000708	CcSEcCtD
Ondansetron—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000127	0.000708	CcSEcCtD
Ondansetron—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.000126	0.000705	CcSEcCtD
Ondansetron—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000126	0.000704	CcSEcCtD
Ondansetron—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.000126	0.000703	CcSEcCtD
Ondansetron—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.000123	0.000686	CcSEcCtD
Ondansetron—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000122	0.000683	CcSEcCtD
Ondansetron—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.000122	0.00068	CcSEcCtD
Ondansetron—Rash—Delavirdine—acquired immunodeficiency syndrome	0.000121	0.000678	CcSEcCtD
Ondansetron—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.000121	0.000677	CcSEcCtD
Ondansetron—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.000121	0.000677	CcSEcCtD
Ondansetron—Headache—Delavirdine—acquired immunodeficiency syndrome	0.00012	0.000673	CcSEcCtD
Ondansetron—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.00012	0.000672	CcSEcCtD
Ondansetron—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000118	0.000657	CcSEcCtD
Ondansetron—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.000117	0.000655	CcSEcCtD
Ondansetron—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.000117	0.000655	CcSEcCtD
Ondansetron—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.000115	0.000646	CcSEcCtD
Ondansetron—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.000113	0.000633	CcSEcCtD
Ondansetron—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.000113	0.000632	CcSEcCtD
Ondansetron—Rash—Ritonavir—acquired immunodeficiency syndrome	0.000112	0.000627	CcSEcCtD
Ondansetron—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.000112	0.000626	CcSEcCtD
Ondansetron—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.000112	0.000625	CcSEcCtD
Ondansetron—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000111	0.000623	CcSEcCtD
Ondansetron—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.000109	0.000608	CcSEcCtD
Ondansetron—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.000108	0.000604	CcSEcCtD
Ondansetron—Rash—Saquinavir—acquired immunodeficiency syndrome	0.000108	0.000603	CcSEcCtD
Ondansetron—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.000108	0.000603	CcSEcCtD
Ondansetron—Headache—Saquinavir—acquired immunodeficiency syndrome	0.000107	0.000599	CcSEcCtD
Ondansetron—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.000104	0.00058	CcSEcCtD
Ondansetron—Rash—Lamivudine—acquired immunodeficiency syndrome	0.000103	0.000576	CcSEcCtD
Ondansetron—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.000103	0.000575	CcSEcCtD
Ondansetron—Headache—Lamivudine—acquired immunodeficiency syndrome	0.000102	0.000572	CcSEcCtD
Ondansetron—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	7.39e-05	0.00624	CbGpPWpGaD
Ondansetron—OPRM1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	7.21e-05	0.00609	CbGpPWpGaD
Ondansetron—HTR4—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	7.04e-05	0.00594	CbGpPWpGaD
Ondansetron—OPRM1—TCR Signaling Pathway—CCR5—acquired immunodeficiency syndrome	7.04e-05	0.00594	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	6.91e-05	0.00583	CbGpPWpGaD
Ondansetron—KCNH2—SIDS Susceptibility Pathways—IL10—acquired immunodeficiency syndrome	6.9e-05	0.00582	CbGpPWpGaD
Ondansetron—OPRM1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	6.64e-05	0.00561	CbGpPWpGaD
Ondansetron—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	6.52e-05	0.0055	CbGpPWpGaD
Ondansetron—KCNH2—Hematopoietic Stem Cell Differentiation—IL6—acquired immunodeficiency syndrome	6.29e-05	0.00531	CbGpPWpGaD
Ondansetron—HTR1A—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	6.22e-05	0.00525	CbGpPWpGaD
Ondansetron—HTR1B—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	6.22e-05	0.00525	CbGpPWpGaD
Ondansetron—OPRM1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	6.01e-05	0.00507	CbGpPWpGaD
Ondansetron—HTR4—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	5.95e-05	0.00502	CbGpPWpGaD
Ondansetron—HTR1B—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	5.74e-05	0.00485	CbGpPWpGaD
Ondansetron—OPRM1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	5.65e-05	0.00477	CbGpPWpGaD
Ondansetron—OPRM1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	5.65e-05	0.00477	CbGpPWpGaD
Ondansetron—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	5.63e-05	0.00475	CbGpPWpGaD
Ondansetron—HTR1B—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	5.63e-05	0.00475	CbGpPWpGaD
Ondansetron—SLC47A1—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	5.62e-05	0.00474	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	5.49e-05	0.00464	CbGpPWpGaD
Ondansetron—HTR1B—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	5.4e-05	0.00456	CbGpPWpGaD
Ondansetron—HTR1B—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	5.4e-05	0.00456	CbGpPWpGaD
Ondansetron—HTR4—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	5.36e-05	0.00453	CbGpPWpGaD
Ondansetron—HTR1B—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	5.33e-05	0.0045	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	5.27e-05	0.00445	CbGpPWpGaD
Ondansetron—OPRM1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	5.07e-05	0.00428	CbGpPWpGaD
Ondansetron—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	5.05e-05	0.00426	CbGpPWpGaD
Ondansetron—HTR1B—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	5.01e-05	0.00423	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	4.97e-05	0.00419	CbGpPWpGaD
Ondansetron—OPRM1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	4.76e-05	0.00402	CbGpPWpGaD
Ondansetron—OPRM1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	4.76e-05	0.00402	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	4.74e-05	0.004	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	4.72e-05	0.00399	CbGpPWpGaD
Ondansetron—OPRM1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	4.7e-05	0.00397	CbGpPWpGaD
Ondansetron—HTR4—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	4.7e-05	0.00397	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	4.65e-05	0.00393	CbGpPWpGaD
Ondansetron—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	4.57e-05	0.00385	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	4.51e-05	0.00381	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	4.51e-05	0.00381	CbGpPWpGaD
Ondansetron—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	4.46e-05	0.00376	CbGpPWpGaD
Ondansetron—SLC47A2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	4.43e-05	0.00374	CbGpPWpGaD
Ondansetron—OPRM1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	4.42e-05	0.00373	CbGpPWpGaD
Ondansetron—HTR4—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	4.42e-05	0.00373	CbGpPWpGaD
Ondansetron—HTR4—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	4.42e-05	0.00373	CbGpPWpGaD
Ondansetron—OPRM1—TCR Signaling Pathway—CD4—acquired immunodeficiency syndrome	4.42e-05	0.00373	CbGpPWpGaD
Ondansetron—HTR1A—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	4.37e-05	0.00369	CbGpPWpGaD
Ondansetron—HTR1A—SIDS Susceptibility Pathways—IL10—acquired immunodeficiency syndrome	4.33e-05	0.00365	CbGpPWpGaD
Ondansetron—OPRM1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	4.3e-05	0.00363	CbGpPWpGaD
Ondansetron—HTR1B—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	4.29e-05	0.00362	CbGpPWpGaD
Ondansetron—HTR1B—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	4.29e-05	0.00362	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	4.29e-05	0.00362	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	4.27e-05	0.0036	CbGpPWpGaD
Ondansetron—HTR1A—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	4.11e-05	0.00347	CbGpPWpGaD
Ondansetron—HTR1A—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	4.11e-05	0.00347	CbGpPWpGaD
Ondansetron—HTR1B—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	4.11e-05	0.00347	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.08e-05	0.00345	CbGpPWpGaD
Ondansetron—HTR1A—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	4.06e-05	0.00343	CbGpPWpGaD
Ondansetron—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	4.03e-05	0.0034	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	4.01e-05	0.00339	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	4.01e-05	0.00339	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	4.01e-05	0.00339	CbGpPWpGaD
Ondansetron—OPRM1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	3.87e-05	0.00327	CbGpPWpGaD
Ondansetron—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	3.85e-05	0.00325	CbGpPWpGaD
Ondansetron—HTR1B—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	3.84e-05	0.00324	CbGpPWpGaD
Ondansetron—HTR1A—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	3.82e-05	0.00322	CbGpPWpGaD
Ondansetron—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	3.79e-05	0.0032	CbGpPWpGaD
Ondansetron—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	3.79e-05	0.0032	CbGpPWpGaD
Ondansetron—HTR3A—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	3.79e-05	0.0032	CbGpPWpGaD
Ondansetron—HTR1B—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	3.7e-05	0.00312	CbGpPWpGaD
Ondansetron—OPRM1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	3.62e-05	0.00306	CbGpPWpGaD
Ondansetron—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	3.48e-05	0.00294	CbGpPWpGaD
Ondansetron—HTR1B—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	3.48e-05	0.00293	CbGpPWpGaD
Ondansetron—HTR1B—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	3.43e-05	0.0029	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	3.39e-05	0.00286	CbGpPWpGaD
Ondansetron—HTR4—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.36e-05	0.00284	CbGpPWpGaD
Ondansetron—HTR4—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.31e-05	0.0028	CbGpPWpGaD
Ondansetron—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	3.27e-05	0.00276	CbGpPWpGaD
Ondansetron—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	3.27e-05	0.00276	CbGpPWpGaD
Ondansetron—HTR1B—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	3.27e-05	0.00276	CbGpPWpGaD
Ondansetron—HTR1B—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	3.27e-05	0.00276	CbGpPWpGaD
Ondansetron—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	3.27e-05	0.00276	CbGpPWpGaD
Ondansetron—OPRM1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	3.27e-05	0.00276	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	3.19e-05	0.0027	CbGpPWpGaD
Ondansetron—HTR1A—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	3.13e-05	0.00264	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	3.11e-05	0.00263	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	3.07e-05	0.00259	CbGpPWpGaD
Ondansetron—HTR3A—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	3.06e-05	0.00258	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.05e-05	0.00258	CbGpPWpGaD
Ondansetron—OPRM1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	3.03e-05	0.00256	CbGpPWpGaD
Ondansetron—HTR4—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.03e-05	0.00256	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.01e-05	0.00254	CbGpPWpGaD
Ondansetron—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	2.94e-05	0.00248	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—acquired immunodeficiency syndrome	2.93e-05	0.00247	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	2.93e-05	0.00247	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	2.89e-05	0.00244	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	2.88e-05	0.00243	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	2.88e-05	0.00243	CbGpPWpGaD
Ondansetron—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	2.88e-05	0.00243	CbGpPWpGaD
Ondansetron—SLC47A1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	2.86e-05	0.00241	CbGpPWpGaD
Ondansetron—HTR1A—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	2.82e-05	0.00238	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	2.82e-05	0.00238	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.79e-05	0.00235	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.75e-05	0.00232	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	2.75e-05	0.00232	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	2.65e-05	0.00224	CbGpPWpGaD
Ondansetron—KCNH2—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	2.62e-05	0.00222	CbGpPWpGaD
Ondansetron—HTR1A—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	2.62e-05	0.00221	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—acquired immunodeficiency syndrome	2.6e-05	0.0022	CbGpPWpGaD
Ondansetron—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	2.6e-05	0.00219	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	2.55e-05	0.00215	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.52e-05	0.00213	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—TAT—acquired immunodeficiency syndrome	2.52e-05	0.00213	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	2.49e-05	0.0021	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	2.49e-05	0.0021	CbGpPWpGaD
Ondansetron—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	2.49e-05	0.0021	CbGpPWpGaD
Ondansetron—HTR1B—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	2.49e-05	0.0021	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	2.45e-05	0.00207	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	2.43e-05	0.00205	CbGpPWpGaD
Ondansetron—OPRM1—TCR Signaling Pathway—IL6—acquired immunodeficiency syndrome	2.39e-05	0.00202	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.37e-05	0.002	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.37e-05	0.002	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	2.37e-05	0.002	CbGpPWpGaD
Ondansetron—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	2.24e-05	0.00189	CbGpPWpGaD
Ondansetron—HTR1B—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	2.24e-05	0.00189	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	2.2e-05	0.00186	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	2.19e-05	0.00185	CbGpPWpGaD
Ondansetron—HTR3A—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	2.16e-05	0.00183	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—AGPS—acquired immunodeficiency syndrome	2.14e-05	0.00181	CbGpPWpGaD
Ondansetron—KCNH2—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	2.12e-05	0.00179	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	2.09e-05	0.00177	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	1.98e-05	0.00167	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.97e-05	0.00167	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	1.96e-05	0.00166	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—acquired immunodeficiency syndrome	1.9e-05	0.0016	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	1.9e-05	0.0016	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	1.89e-05	0.0016	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.89e-05	0.00159	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.89e-05	0.00159	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.85e-05	0.00156	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.85e-05	0.00156	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—TAT—acquired immunodeficiency syndrome	1.82e-05	0.00154	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—TAT—acquired immunodeficiency syndrome	1.82e-05	0.00154	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.8e-05	0.00152	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.78e-05	0.00151	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.78e-05	0.0015	CbGpPWpGaD
Ondansetron—HTR4—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.75e-05	0.00148	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.74e-05	0.00147	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	1.73e-05	0.00146	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	1.71e-05	0.00144	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.71e-05	0.00144	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.68e-05	0.00142	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.68e-05	0.00142	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.66e-05	0.00141	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.66e-05	0.00141	CbGpPWpGaD
Ondansetron—HTR1A—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	1.65e-05	0.00139	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.63e-05	0.00138	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.63e-05	0.00138	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.63e-05	0.00137	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.59e-05	0.00134	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.57e-05	0.00133	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—AGPS—acquired immunodeficiency syndrome	1.55e-05	0.00131	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—AGPS—acquired immunodeficiency syndrome	1.55e-05	0.00131	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.51e-05	0.00127	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.5e-05	0.00127	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	1.5e-05	0.00126	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.48e-05	0.00125	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.48e-05	0.00125	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.44e-05	0.00121	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.44e-05	0.00121	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.41e-05	0.00119	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.41e-05	0.00119	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.41e-05	0.00119	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.38e-05	0.00117	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.36e-05	0.00115	CbGpPWpGaD
Ondansetron—HTR1A—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	1.33e-05	0.00112	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.3e-05	0.0011	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—TAT—acquired immunodeficiency syndrome	1.29e-05	0.00109	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—TAT—acquired immunodeficiency syndrome	1.28e-05	0.00108	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.28e-05	0.00108	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.28e-05	0.00108	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.28e-05	0.00108	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.27e-05	0.00107	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.26e-05	0.00106	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.24e-05	0.00105	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.22e-05	0.00103	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.17e-05	0.000984	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.15e-05	0.00097	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.13e-05	0.000951	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.12e-05	0.000943	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.11e-05	0.000936	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—AGPS—acquired immunodeficiency syndrome	1.1e-05	0.000929	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—TAT—acquired immunodeficiency syndrome	1.1e-05	0.000926	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—AGPS—acquired immunodeficiency syndrome	1.09e-05	0.000921	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.07e-05	0.000904	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.05e-05	0.00089	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.05e-05	0.00089	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.03e-05	0.000868	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.01e-05	0.000856	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	9.91e-06	0.000836	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	9.91e-06	0.000836	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	9.72e-06	0.000821	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	9.64e-06	0.000814	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	9.58e-06	0.000808	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—IL2—acquired immunodeficiency syndrome	9.39e-06	0.000793	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	9.35e-06	0.000789	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—AGPS—acquired immunodeficiency syndrome	9.33e-06	0.000787	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	9.3e-06	0.000785	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	8.88e-06	0.000749	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	8.76e-06	0.000739	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	8.74e-06	0.000738	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	8.74e-06	0.000738	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	8.47e-06	0.000715	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	8.03e-06	0.000678	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	7.55e-06	0.000637	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	7.55e-06	0.000637	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	7.54e-06	0.000636	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	7.43e-06	0.000627	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	7.31e-06	0.000617	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	7.2e-06	0.000608	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.79e-06	0.000573	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	6.65e-06	0.000562	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	6.64e-06	0.000561	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	6.55e-06	0.000553	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	6.46e-06	0.000545	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	5.99e-06	0.000506	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	5.86e-06	0.000495	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	5.74e-06	0.000485	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	5.66e-06	0.000477	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	5.57e-06	0.00047	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.52e-06	0.000466	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	5.17e-06	0.000437	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	5.06e-06	0.000427	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	5.03e-06	0.000424	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—ALB—acquired immunodeficiency syndrome	4.39e-06	0.000371	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	4.29e-06	0.000363	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.92e-06	0.000331	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.9e-06	0.00033	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.46e-06	0.000292	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.45e-06	0.000291	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—ALB—acquired immunodeficiency syndrome	3.18e-06	0.000269	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—ALB—acquired immunodeficiency syndrome	3.18e-06	0.000268	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.99e-06	0.000252	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.97e-06	0.000251	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.31e-06	0.000195	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	2.26e-06	0.000191	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—ALB—acquired immunodeficiency syndrome	2.24e-06	0.000189	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.04e-06	0.000172	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—ALB—acquired immunodeficiency syndrome	1.91e-06	0.000161	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.76e-06	0.000148	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	1.48e-06	0.000125	CbGpPWpGaD
